[go: up one dir, main page]

FI97444B - Förfarande för framställning av ett läkemedelsavgivande system - Google Patents

Förfarande för framställning av ett läkemedelsavgivande system Download PDF

Info

Publication number
FI97444B
FI97444B FI895555A FI895555A FI97444B FI 97444 B FI97444 B FI 97444B FI 895555 A FI895555 A FI 895555A FI 895555 A FI895555 A FI 895555A FI 97444 B FI97444 B FI 97444B
Authority
FI
Finland
Prior art keywords
insulin
microspheres
administration
drug
nasal
Prior art date
Application number
FI895555A
Other languages
English (en)
Finnish (fi)
Other versions
FI895555A0 (sv
FI97444C (sv
Inventor
Lisbeth Illum
Original Assignee
Danbiosyst Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk filed Critical Danbiosyst Uk
Publication of FI895555A0 publication Critical patent/FI895555A0/sv
Application granted granted Critical
Publication of FI97444B publication Critical patent/FI97444B/sv
Publication of FI97444C publication Critical patent/FI97444C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (14)

1. Förfarande för framställning av ett läkemedelsavgivande system för transmukosal avgivning, vilket system innehäller ett flertal mikrosfärpartiklar, som innehäller ett aktivt lä-kemedel och ett med varje partikel förbundet material, som har 30 egenskapen att öka det aktiva läkemedlets biotillgänglighet over ett slemhinnemembran, kannetecknat av att förfarandet omfattar följande steg: i) framställning av mikrosfärpartiklar, ii) införlivande av det aktiva läkemedlet och materialet un- 35 der framställningen av mikrosfärerna eller sorbering av läkemedlet och materialet in i eller pä mikrosfärerna efter deras framställning, och ; iii) möjligen frystorkning av produkten frän steg ii). 97444
2. Förfarande enligt patentkrav 1, kännetecknat av att de framställda mikrosfärerna har en storlek mellan 10 och 100 μιη.
3. Förfarande enligt patentkrav 1 eller 2, kannetecknat av 5 att materialet är ett ytaktivt material.
4. Förfarande enligt nägot av föregäende patentkrav, känne-tecknat av att mikrosfärerna framställes frän stärkelse, stär-kelsederivat, gelatin, albumin, kollagen, dextran eller dext- 10 randerivat.
5. Förfarande enligt patentkrav 4, kannetecknat av att mikrosfärerna framställes frän stärkelse. 15
6. Förfarande enligt nägot av patentkraven 1-3, kännetecknat av att mikrosfärerna bildas frän det aktiva läkemedlet självt.
7. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att det ytterligare omfattar ett steg där mikrosfä- 20 rerna tvärbindes.
8. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att det material, som ökar biotillgängligheten, är ett lysofosfatidylkolin. 25
9. Förfarande enligt nägot av patentkraven 3-7, kännetecknat av att det ytaktiva medlet är ett ickejoniskt ytaktivt medel.
10. Förfarande enligt nägot av föregäende patentkrav, känne-30 tecknat av att den framställda kompositionen är avsedd för intranasal ingivning.
11. Förfarande enligt nägot av föregäende patentkrav, kännetecknat av att läkemedlet är en biologiskt aktiv polypeptid 35 eller ett derivat därav med en molekylvikt frän 1000 tili 300000.
12. Förfarande enligt patentkrav 11, kännetecknat av att po- lypeptiden är insulin eller tillväxthormon. Il
FI895555A 1987-05-22 1989-11-21 Förfarande för framställning av ett läkemedelsavgivande system FI97444C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8712176 1987-05-22
GB878712176A GB8712176D0 (en) 1987-05-22 1987-05-22 Drug delivery system
GB8800396 1988-05-20
PCT/GB1988/000396 WO1988009163A1 (en) 1987-05-22 1988-05-20 Enhanced uptake drug delivery system

Publications (3)

Publication Number Publication Date
FI895555A0 FI895555A0 (sv) 1989-11-21
FI97444B true FI97444B (sv) 1996-09-13
FI97444C FI97444C (sv) 1996-12-27

Family

ID=10617794

Family Applications (1)

Application Number Title Priority Date Filing Date
FI895555A FI97444C (sv) 1987-05-22 1989-11-21 Förfarande för framställning av ett läkemedelsavgivande system

Country Status (10)

Country Link
EP (1) EP0391896B1 (sv)
JP (1) JP2914670B2 (sv)
AU (1) AU614290B2 (sv)
CA (1) CA1324079C (sv)
DE (1) DE3888201T2 (sv)
DK (1) DK175316B1 (sv)
FI (1) FI97444C (sv)
GB (2) GB8712176D0 (sv)
NO (1) NO178564C (sv)
WO (1) WO1988009163A1 (sv)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318512B1 (en) * 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
AU639228B2 (en) * 1989-02-17 1993-07-22 Transave, Inc. Lipid excipient for nasal delivery and topical application
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
IL93925A0 (en) * 1989-03-29 1990-12-23 Alcon Lab Inc Pharmaceutical compositions containing a monoacyl phosphogylceride
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
GB2237510B (en) * 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP1013270A3 (en) * 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5549908A (en) * 1993-05-20 1996-08-27 The University Of Akron Hydrolytically labile microspheres of polysaccharide crosslinked with cyanogen halide and their application in wound dressings
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CZ295827B6 (cs) 1994-03-07 2005-11-16 Nektar Therapeutics Způsob aerosolizace dávky inzulinu, inzulinový přípravek a jeho použití
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
EE9700138A (et) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosoolravimvormid
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
CA2206657C (en) 1994-12-22 2009-05-19 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, pth
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
JP2000290184A (ja) * 1999-04-01 2000-10-17 Kyowa Hakko Kogyo Co Ltd 経鼻投与製剤
US7833549B2 (en) * 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
CA2433335C (en) 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
WO2003026699A1 (fr) * 2001-09-26 2003-04-03 Tanabe Seiyaku Co., Ltd. Compositions medicinales favorisant l'absorption de medicaments
AU2002352836B2 (en) 2001-11-20 2005-09-29 Alkermes, Inc. Improved particulate compositions for pulmonary delivery
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
NL1022442C2 (nl) * 2003-01-20 2004-07-22 Tno Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.
WO2004078211A1 (ja) * 2003-03-04 2004-09-16 Tanabe Seiyaku Co., Ltd. 粉末経鼻投与製剤
US20050031549A1 (en) * 2003-06-09 2005-02-10 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of growth hormone
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
ES2848210T3 (es) 2014-01-27 2021-08-05 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nanoencapsulación de compuestos activos hidrófilos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681500A (en) * 1969-12-12 1972-08-01 Boehringer Sohn Ingelheim Spray compositions for treatment of obstructive disorders of the respiratory tract and methods therefor
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
EP0257915B1 (en) * 1986-08-11 1993-03-10 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules

Also Published As

Publication number Publication date
FI895555A0 (sv) 1989-11-21
DK583789D0 (da) 1989-11-21
FI97444C (sv) 1996-12-27
EP0391896B1 (en) 1994-03-02
AU1793188A (en) 1988-12-21
DE3888201D1 (de) 1994-04-07
DE3888201T2 (de) 1994-07-14
WO1988009163A1 (en) 1988-12-01
NO178564B (no) 1996-01-15
NO890283D0 (no) 1989-01-23
NO890283L (no) 1989-01-23
EP0391896A1 (en) 1990-10-17
AU614290B2 (en) 1991-08-29
DK175316B1 (da) 2004-08-16
NO178564C (no) 1996-04-24
GB8924696D0 (en) 1990-09-05
GB8712176D0 (en) 1987-06-24
CA1324079C (en) 1993-11-09
GB2231495A (en) 1990-11-21
GB2231495B (en) 1991-08-28
JPH02503915A (ja) 1990-11-15
JP2914670B2 (ja) 1999-07-05
DK583789A (da) 1990-01-18

Similar Documents

Publication Publication Date Title
FI97444B (sv) Förfarande för framställning av ett läkemedelsavgivande system
US5863554A (en) Enhanced uptake drug delivery system
US5744166A (en) Drug delivery compositions
JP3306779B2 (ja) 薬物送達組成物
JP2914671B2 (ja) 薬剤組成物
US5804212A (en) Small particle compositions for intranasal drug delivery
US5554388A (en) Systemic drug delivery compositions comprising a polycationi substance
US5725871A (en) Drug delivery compositions comprising lysophosphoglycerolipid
AU2002220002B2 (en) Methods and compositions for enhanced delivery of bioactive molecules
EP2308473A1 (en) Pharmaceutical composition containing surface-coated microparticles
CA2060176C (en) Small particle drug compositions
EP1722759B1 (en) Composition containing chitosan and a polyol-phosphate or a sugar-phosphate
JPH05508616A (ja) 治療用エアロゾル剤
CN1180569A (zh) 经鼻给药用制剂
KR20120084303A (ko) 약물 함유 미립자를 포함하는 의약 조성물 및 그 제조 방법
EP0487562B1 (en) Pharmaceutical compositions
JPH08277226A (ja) 経鼻吸収用生理活性ペプチド組成物
JP4387018B2 (ja) 経肺投与用医薬品組成物
AU617376C (en) A drug composition with microspheres and process for its preparation

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: WEST PHARMACEUTICAL SERVICES DRUG DELIVERY & CLINI

MA Patent expired